Infinite

Scale

Simulating life. Accelerating cures.™

The world’s first Simulative AI platform capable of generating
precise Human Digital Cell Clones with drug interactions in minutes.

 

Problem

  • Success is the exception not the norm due to the poor translation of animal testing to human outcomes.

  • And with it, the opportunity to repurpose 500,000+ drugs/compounds*.

  • The use of 115 Million+ animals raises ethics, costs, and still produces poor outcomes.

Need

  • Real-world patient-derived digital cell clones to provide accurate preclinical results, saving time and cost.

  • Build precise Human Digital Cell Clones drug interactions in seconds using infinitusbio.AI technology.

  • Strengthening animal model results for robust IND-enabling submissions, eventually eliminating animals in Pharma R&D over time.

Solution

  • infinitusbio.AI has built a reference human digital stem cell reasoning model to produce the most advanced mechanistic digital cell simulations via a Digital Cell Differentiation™ process

  • This platform can scale without requiring the huge amounts of computing power and data needed by others

    • It can produce highly unique and powerful cell simulations that predict dynamic cellular responses

    • It is based on a next-gen AI technology called KHAi.net™ (Self-organizing Macro-connectionist Agent Network)

  • Robust human model. The process takes seconds, needs no training data and requires only patient gene expression data to differentiate the reference model.

    Proven solution -

    • Our human digital cell clones have been successfully used for cancer and autoimmune disorders (IBD)

    • Leveraging cell as the fundamental unit of biology, we’ve created value across drug R&D

The first generation of KHAi.net™ was successfully used in Dr. Pham’s AI company (acquired by Nasdaq: EPNY for $637M). The second generation has allowed the development of the Reference Human Cell Intelligent Model based on extensive knowledge bases characterizing cellular structure and function, and then further refined with gene expression data to produce specific human digital clones of interest by combining both data and deep domain knowledge.

What our partners say about infinitusbio.AI

“This will revolutionize genomics because we can now model the genome and obtain answers in a way that is otherwise impractical today, with current technologies.”

Dr. Yo Suzuki, PhD, Associate Professor, J. Craig Venter Institute.

“We’re thrilled to enter this collaboration to advance our oncology drug programs with infinitusbio.AI’s AI Digital Cell Clone Lab platform. Integrating AI powered solutions into our research processes aligns with our aim to adopt smarter practices in our R&D, in order to broaden drug application to more cancer types and speed up the time it takes to bring new drugs to patients,”

Bertrand Ducrey, CEO of Debiopharm.